Matthew Meriggioli to Treatment Outcome
This is a "connection" page, showing publications Matthew Meriggioli has written about Treatment Outcome.
Connection Strength
0.525
-
The Clinical Spectrum of Necrotizing Autoimmune Myopathy: A Mixed Bag With Blurred Lines. JAMA Neurol. 2015 Sep; 72(9):977-9.
Score: 0.261
-
Safety, tolerability, and preliminary efficacy of an IGF-1 mimetic in patients with spinal and bulbar muscular atrophy: a randomised, placebo-controlled trial. Lancet Neurol. 2018 12; 17(12):1043-1052.
Score: 0.081
-
Granulocyte macrophage colony-stimulating factor treatment of a patient in myasthenic crisis: effects on regulatory T cells. Muscle Nerve. 2012 Sep; 46(3):449-53.
Score: 0.053
-
Mycophenolate mofetil for myasthenia gravis: an analysis of efficacy, safety, and tolerability. Neurology. 2003 Nov 25; 61(10):1438-40.
Score: 0.029
-
Efficacy and safety of iscalimab, a novel anti-CD40 monoclonal antibody, in moderate-to-severe myasthenia gravis: A phase 2 randomized study. J Clin Neurosci. 2024 Jan; 119:76-84.
Score: 0.029
-
Mycophenolate mofetil for myasthenia gravis: a double-blind, placebo-controlled pilot study. Ann N Y Acad Sci. 2003 Sep; 998:494-9.
Score: 0.028
-
Five-Year Extension Results of the Phase 1 START Trial of Onasemnogene Abeparvovec in Spinal Muscular Atrophy. JAMA Neurol. 2021 07 01; 78(7):834-841.
Score: 0.024
-
Hashimoto encephalopathy with fulminant myocarditis. Pathol Res Pract. 2010 Oct 15; 206(10):720-2.
Score: 0.011
-
Etanercept treatment in corticosteroid-dependent myasthenia gravis. Neurology. 2004 Dec 28; 63(12):2390-2.
Score: 0.008